Ranbaxy to market Daiichi Sankyo’s innovative products in Malaysia

21 Dec 2011 Evaluate

Daiichi Sankyo Company and Ranbaxy laboratories have entered into strategic alliance for synergistic initiative in Malaysia where Ranbaxy will market innovative products originally discovered by Daiichi Sankyo. Following Singapore, this is the company’s second marketing synergy in the ASEAN region.

Ranbaxy will market Cravit (levofloxacin), the synthetic antibacterial agent originally discovered by Daiichi Sankyo, in Malaysia from January 1, 2012. The product is currently commercialized by First Pharmaceutical in Malaysia.

Daiichi Sankyo and First Pharmaceutical have agreed to transfer the marketing rights of Cravit (levofloxacin) from First Pharma to Ranbaxy. First Pharma will continue to be Daiichi Sankyo’s marketing partner for other products (except Cravit) it had in-licensed from Daiichi Sankyo.

Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.